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Our objective was to assess the prognostic value of symptom typicality in patients without
obstructive coronary artery disease (CAD), determined by coronary computed tomographic angi-
ography (CCTA). We identified 4215 patients without prior history of CAD and without obstruc-
tive CAD (<50% CCTA stenosis). CAD severity was categorized as nonobstructive (1%–49%) and
none (0%). Based upon the Diamond-Forrester criteria for angina pectoris, symptom typicality was
classified as asymptomatic, nonanginal, atypical, and typical. Multivariable Cox proportional haz-
ards models were used to assess the risk of major adverse cardiac events (MACE), comprising all-
cause mortality, myocardial infarction, unstable angina, and late revascularization, according to
symptom typicality. Mean patient age was 57.0 12.0 years (54.9% male). During a median
follow-up of 5.3 years (interquartile range, 4.6–5.9 years), MACE were reported in 312 (7.4%)
patients. Among patients with nonobstructive CAD, there was an association between symptom
typicality and MACE (P for interaction = 0.05), driven by increased risk of MACE among those
with typical angina and nonobstructive CAD (hazard ratio: 1.62, 95% confidence interval:
1.06–2.48, P = 0.03). No consistent relationship was found between symptom typicality and
MACE among patients without any CAD (hazard ratio: 0.73, 95% confidence interval: 0.34–1.57,
P = 0.08). In the CONFIRM registry, patients who presented with concomitant typical angina and
nonobstructive CAD had a higher rate of MACE than did asymptomatic patients with nonobstruc-
tive CAD. However, the presence of typical angina did not appear to portend worse prognosis in
patients with no CAD.
KEYWORDS
Coronary Artery Disease, Coronary Computed Tomographic Angiography, Major Adverse
Cardiac Events, Symptom Typicality
1 | INTRODUCTION
Coronary computed tomographic angiography (CCTA) is a noninvasive
imaging modality commonly used in the evaluation of patients with
suspected coronary artery disease (CAD). Favorable test characteris-
tics include high diagnostic performance for ruling out obstructive
CAD.1–3 CCTA is also useful for the detection of nonobstructive CAD,
a condition associated with an increased risk of adverse cardiovascular
outcomes.4 The presence of nonobstructive CAD is particularly impor-
tant given the observation that the majority of plaque ruptures
implicated in acute coronary syndrome arise from nonobstructive
plaques.5–7
Among patients undergoing evaluation for suspected CAD, chest
pain is a frequent symptom that may present a clinical and therapeutic
challenge.8 Although the prognosis of nonobstructive CAD among
patients with chest pain had once been considered to be benign, sev-
eral recent studies using invasive angiography have elucidated the
adverse prognosis associated with nonobstructive CAD.9,10 Previous
investigations have shown that among patients with stable chest pain,
typical angina pectoris provides valuable diagnostic information for
identification of obstructive CAD by invasive coronary angiography.11
In addition, typical angina is associated with higher prevalence of
obstructive CAD on CCTA compared with those without typical
angina.12 However, the prognostic impact of symptom typicality in
patients with nonobstructive CAD by CCTA remains unclear. In the
present study, we sought to determine the extent to which symptom
typicality adds prognostic information in patients without obstructive
CAD by CCTA.
2 | METHODS
2.1 | Study population
The rationale and design of the Coronary CT Angiography Evaluation
for Clinical Outcomes: An International Multicenter (CONFIRM) regis-
try has been previously described.13 For the purposes of this study,
we used data from the CONFIRM long-term follow-up registry that
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included participants with ≥3 years of follow-up. Enrolled were
17 181 patients who underwent CCTA at 17 centers in 9 countries
within North America, Europe, and Asia between December 2002 and
May 2011. Patients were deemed suitable for study inclusion if they
were age ≥ 18 years, had undergone evaluation by CCTA scanner
with ≥64 detector rows, and presented with an interpretable CCTA.
Patients with nonevaluable segments were not included in this analy-
sis. Patients were excluded according to the following criteria: known
prior CAD at the time of CCTA, as defined by prior myocardial infarc-
tion (MI) or coronary revascularization, such as coronary artery bypass
graft surgery and percutaneous coronary intervention (n = 2248);
adverse events on the day of CCTA (n = 50); obstructive CAD
(n = 4644); missing information for baseline factors, including age or
sex (n = 30) as well as symptom typicality (n = 1755); severity of CAD
(n = 434); missing information for major adverse cardiac events
(MACE; n = 3729); and early revascularization <90 days from index
CCTA (n = 322).
Each of the study centers' institutional review boards approved
the study protocol, and all study participants provided written
informed consent.
2.2 | Clinical characteristics and chest pain
categorization
All patients were assessed at the time of CCTA examination. Baseline
demographics and cardiovascular risk factors such as age, sex, hyper-
tension (HTN), diabetes mellitus (DM), dyslipidemia, family history of
premature CAD, and smoking status were obtained. HTN was defined
as a systolic blood pressure > 140 mm Hg or diastolic blood pres-
sure > 90 mm Hg and/or use of antihypertensive medication. DM
was defined by a fasting glucose level > 126 mg/dL and/or use of
antidiabetic medications. Dyslipidemia was defined as a total choles-
terol level > 200 mg/dL and/or the use of lipid-lowering agent. Family
history of premature CAD was defined as a primary relative with a
diagnosis early in life (ie, mother age < 65 years or father age < 55
years). Category of chest pain was based upon the Diamond-
Forrester criteria for angina pectoris14 and categorized as either
asymptomatic, nonanginal, atypical, or typical angina. Symptom typi-
cality was determined through either written survey or interview by a
doctor or allied health professional at each site and documented at
the site level.
2.3 | CCTA performance and interpretation
CCTA data at each site were obtained by utilization of a ≥ 64-detec-
tor-row CT scanner. Each institution analyzed all CCTA images. Data
acquisition, image postprocessing, and data interpretation of CCTA
adhered to the guidelines of the Society of Cardiovascular Computed
Tomography (SCCT).15,16 The definition of coronary atherosclerosis
was any lesion ≥1 mm2 that existed either within the lumen of the
coronary artery or adjacent to the coronary artery lumen that could
be distinguished from surrounding pericardial tissue, epicardial fat, or
the artery lumen itself. CAD was defined as the presence of any pla-
que in the coronary artery. Nonobstructive CAD was defined as coro-
nary artery segment plaque with a luminal diameter stenosis >0%
and < 50%. Patients with 0% stenosis or a normal CCTA were consid-
ered to have no CAD. For further reliability and accuracy, all identified
lesions were interrogated via numerous methods such as maximum-
intensity-projection and multiplanar-reconstruction techniques along
several longitudinal axes and in the transverse plane.
2.4 | Study outcome
The primary outcome was a composite of MACE including all-cause
mortality (ACM), nonfatal MI, unstable angina, and late target-vessel
revascularization (>90 days). Specific causes of death were not
recorded in the CONFIRM registry. Trained personnel from each site
adjudicated ACM by direct interview with physicians or by querying
national medical databases. Other events such as MI and late target
revascularization were collected via a combination of direct question-
ing of patients using a scripted interview and examination of the
patients' medical records as previously described.13
2.5 | Statistical methods
Continuous variables are reported as mean SD, and categorical vari-
ables are presented as counts with percentages. We compared differ-
ences between continuous variables using a Student t test.
Differences between categorical variables were compared with a χ2 or
Fisher exact test, as appropriate. Incidence of MACE per 1000
person-years was estimated by dividing the number of MACE by the
absolute number of person-years at risk. We evaluated the relation-
ship between symptom typicality and MACE according to the severity
of CAD using the Kaplan–Meier method with log-rank tests for equal-
ity. Unadjusted and multivariable Cox regression models were used to
calculate hazard ratios (HR) with 95% confidence intervals (CI) and
identify associations between symptom typicality and MACE in
patients without obstructive CAD, as well as for comparisons between
nonobstructive CAD and no CAD. Candidate variables were selected
for consideration in multivariable models based on a priori clinical
knowledge. In the first model (Model 1), variables with significant uni-
variate associations (P < 0.05) between both the predictor of interest
(symptom typicality) and outcome (MACE) were included in a back-
ward stepwise selection process with a covariant retention threshold
set at P < 0.05. Model 1 included age, HTN, and DM. In an additional
analysis (Model 2), we further adjusted for clinically important risk fac-
tors not selected in the stepwise selection process. Model 2 included
age, sex, HTN, DM, dyslipidemia, family history of CAD, and current
smoking. We performed additional sensitivity analyses adjusting for
estimated Framingham risk and excluding late revascularization from
the composite outcome.
The prognostic utility of symptom typicality was further assessed
by use of the likelihood ratio test, wherein symptom typicality and
CAD extent by likelihood ratio tests were compared by use of Cox
proportional regression models with and without tests for interaction.
All statistical analyses were performed using Stata software, version
14 (StataCorp LP, College Station, TX), and a 2-tailed P value <0.05
was considered statistically significant.
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3 | RESULTS
Of 4215 patients included in the study, 1848 (43.8%), 498 (11.8%),
1497 (35.5%), and 372 (8.8%) were asymptomatic or had nonanginal,
atypical, and typical angina, respectively. Overall, the mean age of the
cohort was 57.0 12.0 years and 54.9% were male (Table 1). Partici-
pants with typical angina had a higher prevalence of DM, whereas
those with nonanginal symptoms were older, more likely to smoke,
and had a higher prevalence of HTN and family history of CAD
(P < 0.001 for all). The asymptomatic group was predominantly male
(P < 0.001).
During a median follow-up duration of 5.3 years (interquartile
range, 4.6–5.9 years), there were a total of 312 (7.4%) MACE events,
which included 161 (51.6%) ACM, 85 (27.2%) nonfatal MI or unstable
angina, and 66 (21.2%) late revascularization events. The incidence of
MACE was 7.7% (143/1848), 8.6% (43/498), 6.0% (89/1497), and
10.0% (37/372) in asymptomatic, nonanginal, atypical, and typical
angina patients, respectively. Among patients with typical angina,
12 (32.4%) ACM, 12 (32.4%) nonfatal MI or unstable angina, and
13 (35.2%) late revascularization events occurred. Figure 1 displays
the incidence of MACE per 1000 person-years according to symptom
typicality groups and CAD severity. All symptom groups who had non-
obstructive CAD demonstrated a higher incidence of MACE as com-
pared with the no-CAD group. Notably, the highest incidence of
MACE was observed amongs those with typical angina (43.0 per 1000
person-years), whereas no significant relationships were noted
between symptom typicality and MACE in patients without any CAD.
Typical angina was associated with a higher risk of MACE in
patients with nonobstructive CAD (P = 0.01 by log-rank test),
whereas no association between symptom typicality and risk of MACE
was found in those who had no CAD (P = 0.12 by log-rank test;
Figure 2). Multivariable Cox regression revealed no consistent rela-
tionship between symptom typicality and MACE in the overall cohort
(HR: 1.20, 95% CI: 0.83–1.73, P = 0.09; Table 2), as well as among
those without any CAD (HR: 0.73, 95% CI: 0.34–1.57, P = 0.08).
There was a modest trend toward increased risk of MACE among
those with typical symptoms and nonobstructive CAD (P for interac-
tion = 0.05). This appeared to be driven primarily by increased risk of
MACE among those with typical angina and nonobstructive CAD (HR:
1.62, 95% CI: 1.06–2.48, P = 0.03) compared with asymptomatic
patients with nonobstructive CAD. In contrast, nonanginal pain or
atypical angina was not related to MACE in patients with nonobstruc-
tive CAD. There was no evidence of effect modification by sex in the
relationship between symptom typicality and MACE among patients
with nonobstructive CAD (P for interaction = 0.24).
Patients without any CAD had a favorable prognosis. A higher risk
of MACE was observed for patients with nonobstructive CAD, with a
graded relationship observed according to the number of vessels with
affected plaque (P < 0.001 by log-rank test). In multivariable Cox
regression analysis, the presence of 1-, 2-, and 3-vessel disease
increased the risk of MACE by 2.10 (95% CI: 1.55–2.86), 2.79 (95%
CI: 1.98–3.92), and 3.59 (95% CI: 2.50–5.16), respectively, when com-
pared with no plaque.
In an additional analysis, we compared typical angina with all non-
typical symptoms (including asymptomatic, nonanginal, and atypical
angina). Typical angina in patients with nonobstructive CAD was asso-
ciated with a higher risk of MACE as compared with those with nonty-
pical symptoms and nonobstructive CAD (Model 1, HR: 1.72, 95% CI:
1.16–2.55, P = 0.01; and Model 2, HR: 1.78, 95% CI: 1.20–2.66,
P = 0.01). For those without any CAD, typical angina was not a signifi-
cant predictor of MACE in both multivariable models (Model 1, HR:
0.79, 95% CI: 0.38–1.65, P = 0.52; and Model 2, HR: 0.81, 95% CI:
0.39–1.69, P = 0.57). Furthermore, typical angina was associated with
a higher risk of MACE over time in those with nonobstructive CAD
(P = 0.001 by log-rank test), whereas no relationship was present
between typical angina and MACE in patients diagnosed as having no
CAD by CCTA (P = 0.68 by log-rank test).
We performed a series of sensitivity analyses to evaluate the con-
sistency of our main findings. First, we performed an analysis adjusted
for estimated Framingham risk score. Our results remained consistent
after adjustment for Framingham risk score, with typical symptoms
being associated with a HR of 1.74 (95% CI: 1.15–2.63) for MACE
TABLE 1 Baseline characteristics of patients
Variables Total, N = 4215
Symptom Typicality
Asymptomatic, n = 1848 Nonanginal, n = 498 Atypical, n = 1497 Typical, n = 372 P Value
Demographics
Age, y 57.0  12.0 57.6 11.6 58.9 11.6 55.7 12.2 57.0 13.2 <0.001
Male sex 2315 (54.9) 1140 (61.7) 234 (47.0) 769 (51.4) 172 (46.2) <0.001
Cardiac risk factors
HTN 2066 (49.3) 818 (44.5) 284 (57.3) 762 (51.4) 202 (54.5) <0.001
DM 532 (12.7) 196 (10.7) 79 (15.9) 184 (12.4) 73 (20.0) <0.001
Dyslipidemia 2131 (50.9) 905 (49.3) 277 (55.9) 766 (51.7) 183 (49.5) 0.06
Family history of CAD 1305 (31.4) 485 (26.5) 180 (37.0) 510 (34.6) 130 (35.1) <0.001
Current smoking 705 (16.9) 296 (16.2) 118 (24.0) 235 (15.9) 56 (15.1) <0.001
Extent of CAD by CCTA
No CAD 2274 (54.0) 946 (51.2) 253 (50.8) 848 (56.7) 227 (61.0) <0.001
Nonobstructive CAD 1941 (46.0) 902 (48.8) 245 (49.2) 649 (43.4) 145 (39.0)
Abbreviations: CAD, coronary artery disease; CCTA, coronary computed tomography angiography; DM, diabetes mellitus; HTN, hypertension; SD, standard
deviation. Data are presented as n (%) or mean  SD.
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among patients with nonobstructive CAD. No relationship was
observed between typical symptoms and MACE in patients without
CAD (HR: 0.74, 95% CI: 0.34–1.59). An additional sensitivity analysis
adjusting for estimated Adult Treatment Panel III risk also yielded con-
sistent findings (not shown). In an analysis excluding late revasculari-
zation from the composite outcome of MACE, our finding of a
relationship between typical symptoms and MACE in patients with
nonobstructive CAD was no longer statistically significant (P = 0.06).
4 | DISCUSSION
In a large prospective, international, multicenter registry, we observed
an independent association between typical angina pectoris and
increased risk of MACE among patients with nonobstructive CAD
determined by CCTA. In particular, typical angina among those with
nonobstructive CAD was associated with a 1.6-fold increase in the
risk of MACE, and may therefore portend worse prognosis as com-
pared with asymptomatic patients with nonobstructive CAD. These
findings, however, were largely driven by late revascularization. Con-
versely, we found no relationship between symptom typicality and
MACE in patients with a normal CCTA. These findings underscore the
prognostic significance of typical angina in patients diagnosed as hav-
ing CCTA-visualized nonobstructive CAD in a routine clinical setting.
The current study observations are fitting with some,9,10 but not
all,17–19 prior observations. Previously, several studies documented
that chest pain without obstructive CAD is associated with low rates
of adverse cardiovascular outcomes. However, these studies were lim-
ited by factors such as small sample sizes, limited endpoint ascertain-
ment, and cohorts that may not reflect contemporary clinical
practice.17–19 More recently, the Women's Ischemia Syndrome Evalu-
ation (WISE) study reported that women with symptoms and signs
suggestive of ischemia but without obstructive CAD are at increased
risk of cardiovascular events compared with asymptomatic women,
emphasizing that these women should not be considered low-risk.9
Although the WISE study was limited to women, our study findings in
a population of both men and women enrolled in a contemporary reg-
istry extend the findings of WISE to a broader population.
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Importantly, our main findings were consistent irrespective of sex,
without evidence of effect modification by sex. These findings are in
keeping with a previous analysis from the CONFIRM registry demon-
strating similar prognosis among men and women with nonobstructive
CAD matched for age, symptoms, and risk factors.20
The present study findings are also in keeping with those with of
Jespersen et al., who examined the prognostic implications of stable
angina pectoris in patients without obstructive CAD by invasive coro-
nary angiography (ICA) in a retrospective analysis of 11 223 patients
with suspected stable angina followed for 7.5 years.10 In a multivari-
able model adjusted for several factors such as age, body mass index,
DM, smoking, and use of lipid-lowering agent or antihypertensive
medication, patients with diffuse nonobstructive CAD had a higher
risk of MACE (HR: 1.85, 95% CI: 1.51–2.28, P < 0.001). As a
“lumenogram,” ICA is relatively insensitive for the detection of athero-
sclerosis. Using CCTA, a noninvasive imaging modality, our study fur-
ther extends prior investigations using ICA-based strategies for
evaluating patients with chest pain.9,10
The presence of typical angina is one of the hallmarks of ischemic
heart disease. Although discussing the mechanisms explaining the
relationship between typical angina and MACE in patients with non-
obstructive CAD was beyond the scope of this study, several different
mechanisms are possible. The first plausible scenario is the underesti-
mation of coronary artery stenosis determined by CCTA. Although
CCTA has high negative predictive value, it is possible that underesti-
mation of coronary artery stenosis occurs in the subset of patients
close to the threshold of 50% stenosis. Second, nonobstructive CAD
is a simplistic categorization that describes anatomy without elucida-
tion of factors germane to coronary physiology, such as plaque char-
acteristics. Plaque characteristics by CCTA, such as low-attenuation
plaque, spotty calcification, and positive remodeling, have been shown
to improve the prediction of lesions that cause ischemia.21 In a sub-
study of the Analysis of Coronary Blood Flow Using CT Angiography:
Next Steps (NXT) trial, Gaur et al..22 reported that several characteris-
tics such as noncalcified plaque ≥185 mm3, low-density noncalcified
plaque ≥30 mm3, total plaque volume ≥ 195 mm3, and plaque
length ≥ 30 mm predicted lesion-specific ischemia (fractional flow
reserve ≤0.80) in nonobstructive CAD (≤50% stenosis) as well as
obstructive CAD. Finally, symptoms as a result of myocardial ischemia
may result from endothelial dysfunction, microvascular dysfunction,
or coronary vasopasm.8,23,24 As demonstrated by Graf et al, reduced
coronary flow reserve was found in approximately 65% of patients
with typical angina undergoing positron emission tomography.25 Such
impairment in coronary flow reserve may explain the mechanism by
which patients with typical angina and without obstructive CAD expe-
rience adverse outcomes. Our finding that patients with nonobstruc-
tive disease and typical angina had higher risk of MACE than did
those without typical symptoms likely reflects the identification of
patients with ischemia. Interestingly, we observed no relationship
between symptom typicality and MACE in patients without any CAD,
highlighting the importance of atherosclerosis in the relationship
between symptoms and adverse cardiac events. Assessment of micro-
vascular ischemia by myocardial perfusion imaging was outside the
scope of this study and we are unable to determine the extent to
which patients with no CAD and typical symptoms had evidence of
microvascular ischemia.
Nonobstructive CAD by CCTA is a common clinical finding whose
presence identifies patients at greater risk of cardiovascular events. In
a prospective study of 2583 consecutive patients without prior
known CAD and without obstructive CAD, Lin et al26 revealed that
the presence and extent of nonobstructive plaques enhanced mortal-
ity risk prediction. Our study corroborates and expands the results of
the latter study. We have shown that beyond plaque burden, the pres-
ence of symptoms influences prognosis in patients with nonobstruc-
tive CAD. Our data support the notion that stratification by
symptoms is important in both the decision to refer to CCTA and the
clinical interpretation of CCTA.
4.1 | Study limitations
Our study design is strengthened by the use of a large, contemporary
international registry that reflects real-world patients. However, the
limitations of our study design are noteworthy. Given the observa-
tional nature of this registry, our study may have been prone to
potential biases such as heterogeneity in the population, interobserver
and multisite variability in CCTA interpretation, and residual con-
founding. However, in an effort to minimize such biases, standardized
data definitions were prospectively utilized, and only experienced
CCTA centers with trained experts participated.13 Given our study
design, we were unable to consider the effect of cardiac medications
that may have influenced symptom typicality. The CONFIRM study
design did not allow for determination of cardiac mortality or further
understanding of causes of death in patients with no CAD. However,
prior studies have shown that use of cause-specific death can be inac-
curate due to misclassification or misreporting of death, which can
lead to an overestimation of cardiac deaths.27 There were few “hard”
events in this study, and thus our findings were largely driven by late
revascularization and may reflect the practice that patients with typi-
cal angina were more likely to undergo late revascularization than
were patients without symptoms.
Although the presence of symptoms was prospectively deter-
mined at the time of CCTA, information regarding the typicality of
symptoms was assessed at select enrollment sites and missing in 1755
patients. Further, our null findings with respect to symptom typicality
in patients without any CAD raise a question of whether there was
sufficient power in this group. However, a post hoc power analysis
demonstrated 80% power to detect the observed effect estimates in
both unadjusted and adjusted models, with the exception of typical
angina, which was slightly underpowered at 58% in the unadjusted
model.
5 | CONCLUSION
In this prospective, international registry of patients undergoing
CCTA, we observed an increased risk of MACE including late revascu-
larization among patients who have concomitant typical angina and
nonobstructive CAD, as compared with asymptomatic patients with
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nonobstructive CAD. In contrast, symptoms were not associated with
a worse prognosis in patients without CCTA-visualized CAD.
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